Compare iShares International Treasury Bond ETF (IGOV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Merck & Co., Inc. — how do they compare? iShares International Treasury Bond ETF trades at $40.6, while Merck & Co., Inc. trades at $125.41 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares International Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | MRK | |
|---|---|---|
52-Week High | $43.09 | $129.52 |
52-Week Low | $40.54 | $77.60 |
Market Cap | — | $307.25B |
Sector | — | Health |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, trading at $40.68, is experiencing a slight decline of 0.22% today amid a bearish technical signal, with moving averages indicating strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins, while recent news highlights significant downside risks from global inflationary pressures affecting its bond holdings.
The outlook for IGOV is cautious due to high duration exposure amplifying capital losses in a rising rate environment. Investment opportunities are limited without clear financial metrics, and risks include persistent energy issues and geopolitical tensions that could further impact performance.
Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
